Login to Your Account


Proper name: Darbepoetin alpha
Type: Antianemic
Drug Developer: Amgen Inc.
Location: Thousand Oaks, California
Website: www.amgen.com
Indication(s): To treat anemia associated with chronic renal failure and to treat chemotherapy-induced anemia in patients with nonmyeloid malignancies
Approval Date: September 2001
2007 Revenue: $3.614 billion
Percentage of Amgen's Total Revenue: 24.47 percent


Anemia Indication

To continue reading subscribe now to Top 25 Drug Report

Lear More about Top 25 Drug Report

Already a subscriber? Sign In or Buy now to activate your subscription